




## Active substances set

Search phrase: Malignant bladder cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.



| Nivolumab             | Urothelial carcinoma Nivolumab in combination with<br>cisplatin and gemcitabine is indicated for the first-line<br>treatment of adult patients with unresectable or metastatic<br>urothelial carcinoma. Nivolumab as monotherapy is<br>indicated for the treatment of locally advanced<br>unresectable or metastatic urothelial carcinoma in adults<br>after failure of prior platinum-containing therapy. Adjuvant<br>treatment of urothelial carcinoma Nivolumab as<br>monotherapy is indicated for the adjuvant treatment of<br>adults with muscle invasive urothelial carcinoma (MIUC)<br>with tumour cell PD-L1 expression ≥ 1%, who are at high<br>risk of recurrence after undergoing radical resection of<br>MIUC. | •                                    | REIMBURSEMENT<br>WITH RESTRICTIONS<br>ESMO |
|-----------------------|--|--------------------------------------|--|
| Atezolizumab          | Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): - after prior platinum-containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%.  | •                                    | REIMBURSEMENT<br>WITH RESTRICTIONS<br>ESMO |
| Enfortumab<br>vedotin | Enfortumab Vedotin, in combination with pembrolizumab, is<br>indicated for the first-line treatment of adult patients with<br>unresectable or metastatic urothelial cancer who are<br>eligible for platinum-containing chemotherapy. Enfortumab<br>Vedotin as monotherapy is indicated for the treatment of<br>adult patients with locally advanced or metastatic urothelial<br>cancer who have previously received a platinum-containing<br>chemotherapy and a programmed death receptor-1 or<br>programmed death-ligand 1 inhibitor.   | •                                    | REIMBURSEMENT<br>WITH RESTRICTIONS<br>ESMO |
| Avelumab              | Avelumab is indicated as monotherapy for the first-line<br>maintenance treatment of adult patients with locally<br>advanced or metastatic urothelial carcinoma (UC) who are<br>progression-free following platinum-based chemotherapy.   | <ul><li></li><li></li><li></li></ul> | FULL<br>REIMBURSEMENT<br>ESMO              |